Island Pharma’s drug ISLA-101 for flavivirus infections receives Australian patent
Island Pharma has been granted an Australian patent for its drug ISLA-101, a potential treatment for flavivirus infections such as dengue fever.
The patent expires on April 16, 2034, and the company has been granted a patent for ISLA-101, a potential treatment for flavivirus infections such as dengue fever.
Island CEO Dr. David Foster said the patent reinforces the company’s strategy to rapidly develop antiviral therapies for mosquito-borne viral diseases.
Island shares were up a modest 1.43 percent on the day as of 2 p.m. (AEDT).
Chimeric Therapeutics Doses First Patient in Glioblastoma Trial
Chimeric Therapeutics, a cell therapy biotechnology company, has administered the drug to the first patient in a Phase 1B clinical trial of its CHM 1101 CAR T-cell therapy for the treatment of recurrent and/or progressive glioblastoma multiforme (GBM).
The patient was treated at the Sarah Cannon Transplant and Cell Therapy Program at St. David’s South Austin Medical Center in Austin, Texas.
Chimeric CEO Jennifer Chow said the company believes that only by advancing its clinical development program will it be able to realize the full potential of CHM 1101 to treat patients with recurrent or progressive glioblastoma.
Chimeric was up nearly 3.5 percent on the day as of 2 p.m. AEDT.
Imugene Completes VAXINA Trial Milestone
Imugene announced that its MAST (Metastatic Advanced Solid Tumor) Phase 1 trial evaluating the novel anticancer virus CF33-hNIS (VAXINIA) has now completed certain milestones.
The study has passed Group 4 of the intravenous (IV) arm of the single-agent dose-escalation study and Group 2 of the IV arm of the combination study, in which VAXINIA was co-administered with the blockbuster drug pembrolizumab (KEYTRUDA).
IV Group 5 of the single agent dose escalation study and IV Group 3 of the combination drug study are now open.
Imugene CEO Leslie Chong said the company now has the opportunity to expand the trial to enroll additional cohorts of patients in the dose-escalation portion of the single-agent regimen.
